Autosomal recessive nonsyndromic hearing loss 39
MONDO:0012003An autosomal recessive disorder caused by mutations in the HGF gene, encoding hepatocyte growth factor receptor. It is characterized by profound deafness.
Also known as: autosomal recessive nonsyndromic hearing loss 39, DFNB39, HGF autosomal recessive nonsyndromic deafness, autosomal recessive deafness 39, autosomal recessive nonsyndromic deafness 39, autosomal recessive nonsyndromic deafness caused by mutation in HGF, autosomal recessive nonsyndromic deafness type 39, deafness, autosomal recessive 39
3 clinical trials for this condition and its sub-types, 3 tagged with Autosomal recessive nonsyndromic hearing loss 39 itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New hope for hard-to-treat lung cancer: experimental drug targets MET gene
Disease control OngoingThis study tests an experimental drug called REGN5093 in people with advanced non-small cell lung cancer that has a specific change in the MET gene. The first part finds a safe dose, and the second part checks if the drug can shrink tumors. About 231 participants will take part.
Phase 1/2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New injection hopes to heal scarred vocal cords and restore voice
Symptom relief OngoingThis study tests an injection called KP-100LI for people with vocal fold scars that cause voice problems. About 62 adults will receive either the study drug or a placebo to see if it improves voice function over 24 weeks. The goal is to confirm the treatment is safe and effective…
Phase 3 • Sponsor: Kringle Pharma, Inc. • Aim: Symptom relief
Last updated Jul 08, 2026 00:00 UTC